Table 1.
Patient characteristics
| Characteristic | Patients (n = 80) |
|---|---|
| Age at diagnosis, years (range) | 59 (29–82) |
| Clinical stage, n (%) | |
| IB1 | 13 (16) |
| IB2 | 5 (6) |
| IIA1 | 6 (8) |
| IIA2 | 2 (3) |
| IIB | 25 (31) |
| IIIA | 1 (1) |
| IIIB | 26 (33) |
| IVA | 2 (3) |
| Tumor size at diagnosis, n (%)a | |
| ≤4 cm (small) | 29 (36) |
| 4–6 cm (medium) | 34 (43) |
| >6 cm (large) | 17 (21) |
| Pelvic LNMs, n (%) | |
| Present | 47 (59) |
| Absent | 33 (41) |
| PALN metastases, n (%) | |
| Present | 8 (10) |
| Absent | 72 (90) |
| Histological type, n (%) | |
| SCC | 68 (85) |
| ADC | 11 (14) |
| UC | 1 (1) |
| CCRT, n (%) | |
| Weekly cisplatin (40 mg/m2) | 28 (35) |
| Weekly cisplatin (30 mg/m2) and paclitaxel (50 mg/m2) | 5 (6) |
| None | 47 (59) |
| Brachytherapy method, n (%) | |
| Fletcher–Suit applicator | 66 (82) |
| Fletcher–Suit applicator with Trocar Point Needles | 14 (18) |
aADC = adenocarcinoma, CCRT = concurrent chemoradiotherapy, LNM = lymph node metastasis, MRI = magnetic resonance imaging, PALN = paraaortic lymph node, SCC = squamous cell carcinoma, UC = undifferentiated carcinoma. Maximum tumor diameter on MRI at diagnosis.